When methylation levels were analyzed against clinical outcomes, we found 4 CpG sites around CXCL2, 16 CpG sites around CXCL12, and 3 CpG sites around CXCL14/17 where altered methylation appeared to affect tumor behavior and patients’ outcomes (Table 3). This evidence concerns the gene CXCL12 and neoplasm.